Activated Cardiac Fibroblasts Control Contraction of Human Fibrotic Cardiac Microtissues by a β-Adrenoreceptor-Dependent Mechanism
Open Access
- 19 May 2020
- Vol. 9 (5), 1270
- https://doi.org/10.3390/cells9051270
Abstract
Cardiac fibrosis represents a serious clinical problem. Development of novel treatment strategies is currently restricted by the lack of the relevant experimental models in a human genetic context. In this study, we fabricated self-aggregating, scaffold-free, 3D cardiac microtissues using human inducible pluripotent stem cell (iPSC)-derived cardiomyocytes and human cardiac fibroblasts. Fibrotic condition was obtained by treatment of cardiac microtissues with profibrotic cytokine transforming growth factor β1 (TGF-β1), preactivation of foetal cardiac fibroblasts with TGF-β1, or by the use of cardiac fibroblasts obtained from heart failure patients. In our model, TGF-β1 effectively induced profibrotic changes in cardiac fibroblasts and in cardiac microtissues. Fibrotic phenotype of cardiac microtissues was inhibited by treatment with TGF-β-receptor type 1 inhibitor SD208 in a dose-dependent manner. We observed that fibrotic cardiac microtissues substantially increased the spontaneous beating rate by shortening the relaxation phase and showed a lower contraction amplitude. Instead, no changes in action potential profile were detected. Furthermore, we demonstrated that contraction of human cardiac microtissues could be modulated by direct electrical stimulation or treatment with the β-adrenergic receptor agonist isoproterenol. However, in the absence of exogenous agonists, the β-adrenoreceptor blocker nadolol decreased beating rate of fibrotic cardiac microtissues by prolonging relaxation time. Thus, our data suggest that in fibrosis, activated cardiac fibroblasts could promote cardiac contraction rate by a direct stimulation of β-adrenoreceptor signalling. In conclusion, a model of fibrotic cardiac microtissues can be used as a high-throughput model for drug testing and to study cellular and molecular mechanisms of cardiac fibrosis.Funding Information
- Schweizerische Herzstiftung (2017, 2019 year)
This publication has 36 references indexed in Scilit:
- Myocardial fibrosis predicts ventricular tachyarrhythmiasTrends in Cardiovascular Medicine, 2017
- Cardiac FibrosisCirculation Research, 2016
- β‐adrenergic receptor signalling and its functional consequences in the diseased heartEuropean Journal of Clinical Investigation, 2016
- Cardiac fibrosis and arrhythmogenesis: The road to repair is paved with perilsJournal of Molecular and Cellular Cardiology, 2013
- The pathogenesis of cardiac fibrosisCellular and Molecular Life Sciences, 2013
- Heart-Infiltrating Prominin-1+/CD133+Progenitor Cells Represent the Cellular Source of Transforming Growth Factor β–Mediated Cardiac Fibrosis in Experimental Autoimmune MyocarditisCirculation Research, 2009
- Inhibition of TGF-? signaling exacerbates early cardiac dysfunction but prevents late remodeling after infarctionCardiovascular Research, 2004
- Alterations of β-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-β1American Journal of Physiology-Heart and Circulatory Physiology, 2002
- Transforming Growth Factor-β Function Blocking Prevents Myocardial Fibrosis and Diastolic Dysfunction in Pressure-Overloaded RatsCirculation, 2002
- Resting heart rate and cardiac function in dilated cardiomyopathyInternational Journal of Cardiology, 1999